Auro Laboratories Ltd. (AUROLAB) Share Price Rises 8.25% as Micro Cap Stock Enters Top Gainers Today

Auro Laboratories Ltd. traded at Rs 259.90, up 8.25% today, taking its market capitalisation to Rs 149.64 crore and placing it among the session’s micro cap top gainers.

Auro Laboratories Ltd. Share Price rose to Rs 259.90 on 14 August 2026, up Rs 19.80 or 8.25% from the previous close of Rs 240.10. With a market capitalisation of Rs 149.64 crore, the stock moved into focus as a micro cap top gainer in early trade. The verified data confirms a notable same-day price rise, even though it does not establish a company-specific catalyst behind today’s move.

For investors tracking Auro Laboratories Ltd. Share Price Today, the session stood out because the stock opened at Rs 259.95, also marked its day’s high at Rs 259.95, and stayed well above the previous close despite an intraday low of Rs 253.00. That pattern suggests the re-rating happened right from the open rather than building gradually later in the session. In Stock Market Today terms, that kind of opening gap often draws attention to price action even before broader market narratives develop.

Auro Laboratories Ltd. Stock News is therefore being driven primarily by the verified price event itself. The stock’s valuation metrics, sector positioning and peer standing add useful context: a P/E ratio of 42.36, P/B ratio of 3.23, ROE of 9.47% and ROCE of 12.20% place it in a mixed but comparable zone within the Pharmaceuticals & Drugs industry. As Univest notes, investors will likely monitor whether the price rise sustains relative to its sector benchmark and larger listed peers.

Auro Laboratories Ltd. (AUROLAB) Share Price Today: Price Action Analysis

Auro Laboratories Ltd. (AUROLAB) traded at Rs 259.9. versus the previous close of Rs 240.1, a rise of 8.25%. The stock opened at Rs 259.95, reached Rs 259.95, touched Rs 253. Reported volume was 15.

Auro Laboratories Ltd. (AUROLAB) Fundamental Analysis

Auro Laboratories Ltd. was valued at a P/E ratio of 42.36x, a P/B ratio of 3.23x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 9.47% and ROCE of 12.2%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 5.67, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Auro Laboratories Ltd. Fundamental Analysis shows a micro cap pharmaceutical company with a market capitalisation of Rs 149.64 crore and a P/E ratio of 42.36. That multiple indicates investors are currently paying Rs 42.36 for every rupee of trailing earnings attributed to the company. In isolation, that is simply a valuation measure; its real meaning improves when compared with sector and peer benchmarks later in this article.

The company’s P/B ratio stands at 3.23, which means the stock trades at 3.23 times its book value. This is relevant because book value helps indicate the accounting net worth underpinning each share. Auro Laboratories Ltd. reports earnings per share, or EPS, of Rs 5.67, which provides the earnings base behind the current P/E. Dividend yield is 0, so the current valuation context is not being supported by a historical cash-yield component at the present price.

On profitability, ROE is 9.47% and ROCE is 12.20%. ROE measures how efficiently shareholder capital is being converted into profit, while ROCE looks at returns generated from the broader capital employed in the business. These numbers point to positive operating profitability, but not an exceptionally high return profile versus stronger names in the listed pharmaceutical pack. Even so, they are above zero and provide a base for why investors may still keep Auro Laboratories Ltd. Share Price on their watchlists after today’s move.

For readers looking for Auro Laboratories Ltd. Financial Results context, the currently supplied figures suggest a business that is profitable enough to support positive EPS, but valued at a multiple that deserves careful comparison with industry norms. That is where Univest’s stock analysis becomes useful: today’s price rise is clear, yet the bigger question is whether valuation, returns and scale line up attractively within the Healthcare and Pharmaceuticals & Drugs universe. That naturally leads into ownership structure, sector context and peer comparison.

Sector and Industry Context

Auro Laboratories Ltd. (AUROLAB) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Auro Laboratories Ltd. (AUROLAB) has a P/E ratio of 42.36x, which is above the benchmark median of 24.41x, a difference of +73.54%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Auro Laboratories Ltd. (AUROLAB) has a ROE of 9.47%, which is below the benchmark median of 10.49%, a difference of -9.72%. Auro Laboratories Ltd. (AUROLAB) has a ROCE of 12.2%, which is below the benchmark median of 12.97%, a difference of -5.94%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Auro Laboratories Ltd. operates in Healthcare, specifically in the Pharmaceuticals & Drugs industry. Against a same-industry benchmark of 136 companies, the stock sits near the lower end of the market-cap spectrum by absolute size, but its valuation and profitability metrics are close enough to benchmark medians to keep it relevant for sector-focused investors.

The sector snapshot provides important context for Auro Laboratories Ltd. Share Price. The company’s P/E of 42.36 is above the same-industry median of 24.41, though still below the industry average of 70.52. The benchmark range is wide, from 3.29 to 3299.57 across 104 companies with available P/E data, so the stock is clearly not at an extreme end of the valuation spectrum. Its P/B of 3.23 is also above the benchmark median of 1.75 and above the average of 2.51 across 135 companies, with the broader P/B range running from -10.01 to 16.63.

Profitability tells a more balanced story. Auro Laboratories Ltd. reports ROE of 9.47%, slightly below the industry median of 10.49% but above the average of 8.10%. ROCE of 12.20% is below the industry median of 12.97% and below the average of 15.53%. That suggests the company is not standing out on returns in the way its P/B and P/E suggest on valuation. Its market capitalisation of Rs 149.64 crore is above the same-industry median of Rs 146.81 crore but well below the average of Rs 489.36 crore, reflecting how larger companies lift the benchmark mean.

Viewed together, these data points show why Auro Laboratories Ltd. Stock Analysis requires nuance. The stock is not the cheapest name in the industry on supplied valuation metrics, and its return ratios are close to but generally below benchmark medians. In Univest’s reading, that makes today’s price rise more interesting as a market event than as a stand-alone valuation signal.

Peer Comparison

Auro Laboratories Ltd. (AUROLAB) has a P/E ratio of 42.36x compared with the displayed peer median of 31.94x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 9.47% compares with a peer median of 0% across the companies shown in the table. ROCE stood at 12.2% versus the displayed peer median of 8.31%, providing a capital-efficiency comparison. Auro Laboratories Ltd. (AUROLAB) has a market capitalisation of Rs 149.64 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Auro Laboratories Ltd. sits well below the supplied peers on market capitalisation, which immediately frames it as a much smaller listed participant in the Pharmaceuticals & Drugs segment. At Rs 149.64 crore, it is far smaller than Dishman Carbogen Amcis Ltd. at Rs 2,995.34 crore, Beta Drugs Ltd. at Rs 2,836.87 crore, Hikal Ltd. at Rs 2,619.52 crore, Ind-Swift Laboratories Ltd. at Rs 2,605.37 crore and Panacea Biotec Ltd. at Rs 2,450.34 crore. That size difference matters because micro cap price action can look sharper than larger peers on limited liquidity.

On valuation, Auro Laboratories Ltd. Share Price is attached to a P/E of 42.36. That is higher than Dishman Carbogen Amcis at 31.94 and NGL Fine-Chem at 37.20, but lower than Beta Drugs at 69.35, Fredun Pharmaceuticals at 56.53, Ind-Swift Laboratories at 45.02 and Sai Parenteral’s at 174.73. Its P/B of 3.23 is close to Panacea Biotec’s 3.04 and Sai Parenteral’s 3.19, slightly below Venus Remedies at 3.38, and well below higher-multiple names such as Beta Drugs at 10.97, Fredun Pharmaceuticals at 8.44 and NGL Fine-Chem at 6.46.

Profitability comparison is mixed. Auro Laboratories reports ROE of 9.47% and ROCE of 12.20%. That is stronger than peers with weak or negative return profiles such as Dishman Carbogen Amcis, Ind-Swift Laboratories and Panacea Biotec on ROE, and stronger than Dishman, Ind-Swift, Panacea and Venus Remedies on ROCE. However, it trails stronger operators such as Beta Drugs, Hikal, Solara Active Pharma Sciences, Fredun Pharmaceuticals and NGL Fine-Chem on both major return metrics.

The peer set therefore does not place AUROLAB at either extreme. It is smaller by scale, mid-pack on several valuation measures, and moderate on profitability. That combination helps explain why Auro Laboratories Ltd. Latest News today is largely about the immediate share price gain rather than a clear leadership position within the peer group.

Why Investors Are Watching Auro Laboratories Ltd.

Auro Laboratories Ltd. Share Price has entered the market conversation because today’s 8.25% move is large enough to place the micro cap stock among Top Gainers Today. The opening gap, retention of gains above the previous close and the company’s placement within a closely watched pharmaceutical industry benchmark all add to its relevance in Share Market Today discussions.

• Verified price action: the stock rose Rs 19.80 to Rs 259.90 from Rs 240.10.
• Intraday positioning: it opened at Rs 259.95, which was also the day’s high, with a day low of Rs 253.00.
• Market-cap context: AUROLAB is a Micro Cap stock with a market capitalisation of Rs 149.64 crore.
• Valuation context: P/E is 42.36 and P/B is 3.23, both above the same-industry median.
• Profitability context: ROE is 9.47% and ROCE is 12.20%, indicating positive but not standout returns.
• Sector relevance: it operates in Healthcare, within Pharmaceuticals & Drugs, a benchmark universe of 136 companies.

What should investors monitor next? The main points are whether Auro Laboratories Ltd. Share Price continues to hold above the previous close, how the valuation compares with peers as the session evolves, and whether the stock remains a notable Market Movers candidate despite very light recorded BSE volume. Univest users tracking price, ratios and industry placement can use those factors to separate a one-session spike from a move that keeps attracting attention.

About Auro Laboratories Ltd.

Auro Laboratories Ltd. is part of the Healthcare sector and is categorised within the Pharmaceuticals & Drugs industry. That places the company in one of the broader segments of the Indian stock market where investors often compare valuation, return ratios and market capitalisation across a large listed universe. In the supplied same-industry benchmark, the comparison set spans 136 companies, highlighting how diverse this space is in terms of size, profitability and valuation.

From the available market data, Auro Laboratories Ltd. appears as a smaller listed pharmaceutical player rather than one of the industry heavyweights. Its market capitalisation of Rs 149.64 crore is near the benchmark median of Rs 146.81 crore, but far below the benchmark average of Rs 489.36 crore because larger companies skew the sector mean upward. That size profile is important when reading Auro Laboratories Ltd. Market Cap alongside its price action, since smaller companies can show sharper day-to-day moves.

The company’s current market identity is shaped by its financial profile: P/E of 42.36, P/B of 3.23, ROE of 9.47%, ROCE of 12.20%, EPS of Rs 5.67 and dividend yield of 0. For investors following Auro Laboratories Ltd. Company News, those figures position it as a profitable but modestly scaled pharmaceutical stock whose latest visibility comes from market action rather than a disclosed operating trigger in the supplied data. Univest continues to place that information into context by combining price, sector and peer analysis in one view.

Track Auro Laboratories Ltd. Share Price on Univest

Use Auro Laboratories Ltd. (AUROLAB) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Readers following Auro Laboratories Ltd. Share Price can track the stock on Univest for a consolidated view of live price, day change, market capitalisation, valuation ratios and broader market context. That includes Auro Laboratories Ltd. Share Price Today, 52-week levels when available, peer comparison, sector benchmark positioning and updates tied to Stock News and Market News flows.

For investors who prefer a structured dashboard, Univest also helps connect share price movement with fundamentals such as P/E Ratio, P/B Ratio, ROE, ROCE and EPS, so that a top gainer event is read alongside business-quality indicators rather than in isolation. In sessions like this one, where AUROLAB becomes a focus stock on BSE, that broader context matters as much as the immediate percentage gain.

Frequently Asked Questions

What is Auro Laboratories Ltd. Share Price today?

Ans. Auro Laboratories Ltd. Share Price today was Rs 259.90 at the time of the update. The stock was up Rs 19.80 from the previous close of Rs 240.10, translating into an 8.25% same-day gain on BSE.

Why is Auro Laboratories Ltd. Share Price rising today?

Ans. The supplied data confirms that Auro Laboratories Ltd. Share Price rose 8.25% today and entered the top gainer screen. However, the verified inputs establish the price event itself and do not identify any company-specific catalyst behind the move.

What were the opening, high and low levels for AUROLAB today?

Ans. AUROLAB opened at Rs 259.95, which was also the day’s high, while the day’s low was Rs 253.00. That means the stock moved sharply higher at the open and continued to trade above the previous close.

How much market capitalisation does Auro Laboratories Ltd. have?

Ans. Auro Laboratories Ltd. had a market capitalisation of Rs 149.64 crore in the supplied update. That places it in the Micro Cap category, making today’s 8.25% move especially noticeable in top gainer lists.

What does the valuation of Auro Laboratories Ltd. look like?

Ans. The company trades at a P/E ratio of 42.36 and a P/B ratio of 3.23. Both are above the same-industry medians of 24.41 for P/E and 1.75 for P/B in the Healthcare pharmaceuticals benchmark.

How profitable is Auro Laboratories Ltd. based on supplied metrics?

Ans. Auro Laboratories Ltd. reports ROE of 9.47% and ROCE of 12.20%, indicating positive profitability. Its ROE is below the industry median of 10.49%, while its ROCE is also below the same-industry median of 12.97%.

What is the EPS of Auro Laboratories Ltd.?

Ans. Auro Laboratories Ltd. has an EPS of Rs 5.67 based on the supplied data. EPS reflects earnings attributable to each share and forms the basis for reading the stock’s current P/E ratio of 42.36.

Does Auro Laboratories Ltd. pay a dividend yield currently?

Ans. The supplied data shows a dividend yield of 0 for Auro Laboratories Ltd. That means the current market view in this update is centred on share price movement, valuation and profitability rather than historical cash yield.

How does Auro Laboratories Ltd. compare with pharma peers?

Ans. Auro Laboratories Ltd. is much smaller than supplied peers such as Dishman Carbogen Amcis, Beta Drugs and Hikal on market capitalisation. Its P/E of 42.36 is mid-range, while ROE of 9.47% and ROCE of 12.20% are moderate.

Where can investors track Auro Laboratories Ltd. Share Price updates?

Ans. Investors can track Auro Laboratories Ltd. Share Price on Univest for live price updates, valuation ratios, peer comparison and sector context. That helps place today’s 8.25% gain alongside fundamentals and broader market positioning.